Erythromycin is a protein synthesis inhibitor that binds to the 50S ribosomal subunit of the bacterial ribosome. It is found in the family of antibiotics known as the macrolides. Antibiotics in this group are generally protein synthesis inhibitors. Other macrolides include azithromycin and clarithromycin. Lincomycin and clindamycin are antibiotics that inhibit protein synthesis in bacteria but are not macrolides. The macrolides specifically block translocation reaction during protein synthesis in bacteria once they bind to the 50S ribosomal subunit of the target bacterial pathogen.
CLICK HERE TO BUY PHARMACEUTICAL MICROBIOLOGY TEXTBOOK
SOURCES OF ERYTHROMYCIN
Macrolides are naturally-synthesized by Streptomyces species. Erythromycin is synthesized naturally from a strain of Streptomyces known as S. erythreus. Macrolides can also be semi-synthesized by the chemical modification of their general structure especially by the incorporation of a substituent group into the lactone ring (Figure 1). This chemical modification of the general structure of the macrolides results in the formation of newer macrolides such as azithromycin and clarithromycin.
STRUCTURE OF ERYTHROMYCIN
The chemical structure of macrolides (erythromycin) contains large lactone rings that are linked through glycoside bonds with amino sugars. They generally possess a macrocyclic lactone structure (Figure 1). The macrolides structure is usually composed of a large-membered ring that comprises of about 13-15 carbon molecules which are chemically linked to sugar molecules by glycosidic bonds. The chemical structure of erythromycin is shown in Figure 2.
CLINICAL APPLICATION OF ERYTHROMYCIN
Erythromycin is active against the causative agents of whooping cough (caused by Bordetella pertussis), pneumonia (caused by Streptococcus pneumoniae), diphtheria (caused by Corynebacterium diphtheriae), syphilis (caused by Treponema pallidum) and diarrhea (caused by Campylobacter species). They also have activity against mycoplasmas and Chlamydia species. Azithromycin and clarithromycin have broader activity than erythromycin (the first member of the macrolides). Macrolides can also be used to treat some non-bacterial infections such as toxoplasmosis (caused by Toxoplasma gondii) as well as infections caused by mycobacteria.
SPECTRUM OF ACTIVITY OF ERYTHROMYCIN
Erythromycin and the macrolides are generally bacteriostatic in action. They have broad spectrum of activity since they are active against both pathogenic Gram-positive bacteria and Gram-negative bacteria. Though generally bacteriostatic in action, macrolides can be bactericidal in action to some pathogenic Gram-positive bacteria.
MECHANISM OR MODE OF ACTION OF MACROLIDES
Macrolides including erythromycin, clarithromycin and azithromycin are used to treat a wide variety of infections caused by both Gram-positive and Gram-negative bacteria (Figure 3). Erythromycin and the other macrolides generally inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit of the bacterial ribosome (particularly the 23S rRNA). Binding of the 50S ribosomal subunit by erythromycin inhibits protein elongation (usually mediated by the enzyme, peptidyl transferase). This prevents translocation of the ribosome during protein synthesis. Translocation is the movement of some part of the ribosome (especially the mRNA) to other parts of the ribosome (e.g. tRNA) during protein synthesis. In particular, genetic information required for the synthesis of a particular protein molecule (as encoded in the gene or DNA) are translocated or moved from one part of the ribosome to another after transcription must have taken place. In this case, this genetic information flows from the messenger RNA (mRNA) to the transfer RNA (tRNA), and then to the ribosomal RNA (rRNA) where protein synthesis is completed in the ribosome (the protein synthesizing machinery of the cell). Erythromycin blocks the elongation of the polypeptide chain during synthesis when they reversibly bind to the 50S ribosomal subunit. They are bacteriostatic in action.
BACTERIAL RESISTANCE TO ERYTHROMYCIN
The resistance of pathogenic bacteria to the antibacterial onslaught of the macrolides (including erythromycin) could be due to the influx-efflux mechanism which prevents intracellular accumulation of the drug by actively pumping it out of the cell. Microbial resistance can also occur as a result of alteration of the binding site of the antibiotic on the target organism. The alteration of the binding site of erythromycin on the target bacteria is usually mediated by the methylation of the 23S rRNA receptor, which prevents the binding by the antibiotic.
PHARMACOKINETICS, SIDE EFFECT/TOXICITY OF ERYTHROMYCIN
Erythromycin is easily inactivated by the gastric acid in the gastrointestinal (GIT), and thus they are poorly absorbed by the body when administered orally. However, the macrolides (inclusive of erythromycin) are distributed widely in the body and they are excreted in urine. It is orally absorbed as stearate or estolate salt, and cerebrospinal fluid (CSF) penetration of erythromycin is poor. It is excreted via biliary and feacal route. Erythromycin is acid labile and the absorption of salt formulations of the drug from the gastrointestinal tract is variable. Thus, erythromycin needs to be administered 2 hours before or after a meal. The non-salt (base) form of erythromycin is not well absorbed when taken orally, and it is used for sterilizing the gut before surgery. The clinical usage of erythromycin and other macrolides is usually associated with some undesirable untoward effects such as mild stomach or GIT upset, vomiting, fever, and diarrhea. Macrolides are generally nontoxic antibacterial agents.
Ashutosh Kar (2008). Pharmaceutical Microbiology, 1st edition. New Age International Publishers: New Delhi, India.
Block S.S (2001). Disinfection, sterilization and preservation. 5th edition. Lippincott Williams & Wilkins, Philadelphia and London.
Courvalin P, Leclercq R and Rice L.B (2010). Antibiogram. ESKA Publishing, ASM Press, Canada.
Denyer S.P., Hodges N.A and Gorman S.P (2004). Hugo & Russell’s Pharmaceutical Microbiology. 7th ed. Blackwell Publishing Company, USA. Pp.152-172.
Ejikeugwu Chika, Iroha Ifeanyichukwu, Adikwu Michael and Esimone Charles (2013). Susceptibility and Detection of Extended Spectrum β-Lactamase Enzymes from Otitis Media Pathogens. American Journal of Infectious Diseases. 9(1):24-29.
Finch R.G, Greenwood D, Norrby R and Whitley R (2002). Antibiotic and chemotherapy, 8th edition. Churchill Livingstone, London and Edinburg.
Russell A.D and Chopra I (1996). Understanding antibacterial action and resistance. 2nd edition. Ellis Horwood Publishers, New York, USA.